We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+5.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.8B
AUM Growth
+$97.9M
(+3.6%)
Cap. Flow
-$10.3M
Cap. Flow
% of AUM
-0.37%
Top 10 Holdings %
Top 10 Hldgs %
45.4%
Holding
164
New
19
Increased
21
Reduced
19
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$20.7M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$16.7M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$14.5M |
| 4 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$13.3M |
| 5 |
Johnson & Johnson
JNJ
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$23.6M |
| 2 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
+$12.8M |
| 3 |
Biogen
BIIB
|
+$11.9M |
| 4 |
Amgen
AMGN
|
+$11.4M |
| 5 |
AKRX
Akorn Inc
AKRX
|
+$11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.03% |
| 2 | Real Estate | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$163B
| $227M | 8.11% |
2,801,131
+271,000
| +11% | +$20.7M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $202M | 7.23% |
1,387,525
-69,080
| -5% | -$9.41M |
|
|
3
Biogen
BIIB
$30.7B
| $153M | 5.48% |
489,604
-40,170
| -8% | -$11.9M |
|
|
4
Amgen
AMGN
$209B
| $116M | 4.13% |
620,274
-64,550
| -9% | -$11.4M |
|
5
Vertex Pharmaceuticals
VRTX
$122B
| $111M | 3.97% |
731,123
-66,930
| -8% | -$10.1M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $105M | 3.77% |
750,905
| – | – |
|
|
7
Johnson & Johnson
JNJ
$617B
| $104M | 3.71% |
798,932
+84,570
| +12% | +$11.2M |
|
8
Merck
MRK
$321B
| $94.3M | 3.37% |
1,544,013
| – | – |
|
9
Incyte
INCY
$24.9B
| $80.9M | 2.89% |
693,275
| – | – |
|
10
Regeneron Pharmaceuticals
REGN
$77.4B
| $76.2M | 2.73% |
170,516
-17,150
| -9% | -$8.16M |
|
|
AGN
11
DELISTED
Allergan plc
AGN
| $69.5M | 2.48% |
338,979
+28,369
| +9% | +$6.6M |
|
12
Abbott
ABT
$183B
| $66.7M | 2.39% |
1,250,920
+98,400
| +9% | +$4.94M |
|
13
Illumina
ILMN
$31B
| $63.1M | 2.26% |
325,558
+38,787
| +14% | +$7.22M |
|
14
UnitedHealth
UNH
$383B
| $54M | 1.93% |
275,826
-31,650
| -10% | -$6.11M |
|
15
Viatris
VTRS
$20.7B
| $50.3M | 1.8% |
1,603,112
| – | – |
|
16
BioMarin Pharmaceuticals
BMRN
$11.7B
| $46.7M | 1.67% |
501,745
| – | – |
|
17
Medtronic
MDT
$110B
| $45.1M | 1.61% |
580,326
| – | – |
|
|
18
Thermo Fisher Scientific
TMO
$214B
| $41.4M | 1.48% |
219,072
+79,952
| +57% | +$14.5M |
|
19
Jazz Pharmaceuticals
JAZZ
$16.2B
| $40.1M | 1.43% |
273,916
| – | – |
|
|
SHPG
20
DELISTED
Shire pic
SHPG
| $38.6M | 1.38% |
252,113
| – | – |
|
21
Neurocrine Biosciences
NBIX
$18.7B
| $34.5M | 1.23% |
562,467
| – | – |
|
22
Novartis
NVS
$301B
| $34.2M | 1.22% |
444,907
| – | – |
|
23
CVS Health
CVS
$134B
| $33.5M | 1.2% |
411,891
| – | – |
|
24
Eli Lilly
LLY
$1.03T
| $33.2M | 1.19% |
388,100
-105,000
| -21% | -$8.61M |
|
|
25
Teva Pharmaceuticals
TEVA
$41.2B
| $30.9M | 1.11% |
1,756,558
+740,800
| +73% | +$16.7M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q3 2017 Portfolio in Review
As of Q3 2017, Tekla Capital Management held 164 positions worth $2.8B, up 3.6% from $2.7B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Tekla Capital Management's Q3 2017 filing shows 19 new, 21 increased, 19 reduced and 11 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M. The largest sale was iShares Biotechnology ETF, an estimated $23.6M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Real Estate.
- Tekla Capital Management's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 123,200 shares worth $7.15M.
- Tekla Capital Management added most to Gilead Sciences in Q3 2017, an estimated $20.7M increase.
- Tekla Capital Management's biggest Q3 2017 reduction was Biogen, cutting an estimated $11.9M.
- Tekla Capital Management fully exited iShares Biotechnology ETF in Q3 2017, selling an estimated $23.6M.
- Tekla Capital Management's ten largest holdings make up 45% of its $2.8B portfolio in Q3 2017.
- Tekla Capital Management opened 19 new positions and closed 11 in Q3 2017.
- Tekla Capital Management's portfolio value rose 3.6% quarter-over-quarter to $2.8B.
Based on Tekla Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.